According to a recent research report titled ” Pulmonary Arterial Hypertension Market (By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators; By Type: Branded, Generics; By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032″ published by Precedence Research, the global pulmonary arterial hypertension market size is projected to touch around USD 12.18 billion by 2032 and growing at a CAGR of 5.30% over the forecast period 2023 to 2032. This comprehensive study examines various factors and their impact on the growth of the pulmonary arterial hypertension market.
Key Takeaways
- North America led the market with the largest market share of 41% in 2022.
- Asia-Pacific is projected to grow at a notable CAGR of 13.3% during the forecast period.
- By Drug Class, the prostacyclin and prostacyclin analogs segment has held the major revenue share of 45% in 2022.
- By Drug Class, The SGC simulators segment is anticipated to grow at a CAGR of 5% during the projected period.
- By Type, the branded segment contributed more than 42% of revenue share in 2022.
- By Type, the generics segment is projected to grow at the fastest CAGR over the projected period.
- By Route of Administration, the oral segment generated more than 51% of revenue share in 2022.
- By Route of Administration, the intravenous/ subcutaneous segment is expected to expand at the fastest CAGR over the projected period.
The report primarily focuses on the volume and value of the pulmonary arterial hypertension market at the global, regional, and company levels. At the global level, the report analyzes historical data and future prospects to present an overview of the overall market size. Regionally, the study emphasizes key regions such as North America, Europe, the Middle East & Africa, Latin America, and others.
Furthermore, the research report provides specific segmentations based on regions (countries), companies, and all market segments. This analysis offers insights into the growth and revenue trends during the historical period of 2017 to 2032, as well as the projected period. By understanding these segments, it becomes possible to identify the significance of different factors that contribute to market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3432
The research also highlights significant progressions in both organic and inorganic growth strategies within the global pulmonary arterial hypertension market. Numerous companies are placing emphasis on new product launches, gaining product approvals, and implementing various business expansion tactics. Moreover, the report presents detailed profiles of firms operating in the pulmonary arterial hypertension market, along with their respective market strategies. Additionally, the study concentrates on prominent industry participants, furnishing details such as company profiles, product offerings, financial updates, and noteworthy advancements.
Pulmonary Arterial Hypertension Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.3% |
| Market Size in 2023 | USD 7.65 Billion |
| Market Size by 2032 | USD 12.18 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Type, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: Cadmium Telluride Market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
Market Key Players
The report incorporates company profiles of key players in the market. These profiles encompass vital information such as product portfolio, key strategies, and a comprehensive SWOT analysis for each player. Additionally, the report presents a matrix illustrating the presence of each prominent player, enabling readers to gain actionable insights. This facilitates a thoughtful assessment of the market status and aids in predicting the level of competition in the pulmonary arterial hypertension market.
Some of the prominent players in the pulmonary arterial hypertension market include
- Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
- Gilead Sciences
- United Therapeutics Corporation
- GlaxoSmithKline
- Bayer
- Pfizer
- Arena Pharmaceuticals
- Reata Pharmaceuticals
- Lung Biotechnology
- Acceleron Pharma
- Liquidia Technologies
- SteadyMed Therapeutics (acquired by United Therapeutics)
- Complexa Inc.
- Bellerophon Therapeutics
- Innoven Life Sciences.
Market Segmentations
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Generics
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Table of Contents:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pulmonary Arterial Hypertension Market
5.1. COVID-19 Landscape: Pulmonary Arterial Hypertension Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pulmonary Arterial Hypertension Market, By Drug Class
8.1. Pulmonary Arterial Hypertension Market, by Drug Class, 2023-2032
8.1.1 Endothelin Receptor Antagonists (ERAs)
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. PDE-5 Inhibitors
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Prostacyclin and Prostacyclin Analogs
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. SGC Stimulators
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Pulmonary Arterial Hypertension Market, By Type
9.1. Pulmonary Arterial Hypertension Market, by Type, 2023-2032
9.1.1. Branded
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Generics
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Pulmonary Arterial Hypertension Market, By Route of Administration
10.1. Pulmonary Arterial Hypertension Market, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Intravenous/ subcutaneous
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Inhalational
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Pulmonary Arterial Hypertension Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
Chapter 12. Company Profiles
12.1. Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Gilead Sciences
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. United Therapeutics Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Arena Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Reata Pharmaceuticals
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lung Biotechnology
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Acceleron Pharma
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
This report presents a compelling investment opportunity for those interested in the global pulmonary arterial hypertension market. It serves as an extensive and informative guide, offering clear insights into this niche market. By delving into the report, you will gain a comprehensive understanding of the various major application areas for pulmonary arterial hypertension. Furthermore, it provides crucial information about the key regions worldwide that are expected to experience substantial growth within the forecast period of 2023-2030. Armed with this knowledge, you can strategically plan your market entry approaches.
Moreover, this report offers a deep analysis of the competitive landscape, equipping you with valuable insights into the level of competition prevalent in this highly competitive market. If you are already an established player, it will enable you to assess the strategies employed by your competitors, allowing you to stay ahead as market leaders. For newcomers entering this market, the extensive data provided in this report is invaluable, providing a solid foundation for informed decision-making.
Some of the key questions answered in this report:
- What is the size of the overall Pulmonary arterial hypertension market and its segments?
- What are the key segments and sub-segments in the market?
- What are the key drivers, restraints, opportunities and challenges of the Pulmonary arterial hypertension market and how they are expected to impact the market?
- What are the attractive investment opportunities within the Pulmonary arterial hypertension market?
- What is the Pulmonary arterial hypertension market size at the regional and country-level?
- Who are the key market players and their key competitors?
- What are the strategies for growth adopted by the key players in Pulmonary arterial hypertension market?
- What are the recent trends in Pulmonary arterial hypertension market? (M&A, partnerships, new product developments, expansions)?
- What are the challenges to the Pulmonary arterial hypertension market growth?
- What are the key market trends impacting the growth of Pulmonary arterial hypertension market?
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
